Certain lots of argatroban, a blood thinner often used as an alternative to heparin during PCI, have been recalled due to the presence of particulate matter. The affected products should not be used to treat any patients due to an increased risk of adverse events.
The rise of CCTA continues to be one of modern medicine's biggest stories. An upcoming webinar will explore what cardiologists, executives and other stakeholders need to know about building and growing a productive CCTA program in 2026 and beyond.
The recent PRO-TAVI trial showed that care teams can safely perform PCI at a later date when patients undergoing TAVR present with concomitant coronary artery disease. According to this latest analysis, however, there may still be certain patients who benefit from undergoing PCI prior to TAVR.
William Holding, a veteran healthcare consultant, spoke to Cardiovascular Business about the ever-changing cardiology industry. Should private practices seek a deal or stay independent? How has private equity impacted the market? He answered those questions and many more.
The ACC, SCAI and STS have shared early support for expanding Medicare coverage to include TAVR in patients with native AR. The groups emphasized that CED requirements and multidisciplinary heart team meetings are necessary to ensure patients receive the best possible care going forward.
Cardiology services for approximately 50,000 patients are in the middle of an ongoing legal battle. New York Sen. Jim Tedisco is now publicly calling for New York. Gov. Kathy Hochul to step in and help.
Traditionally, the interventional cardiologist first visualizes the coronary anatomy in detail when contrast is injected in the catheterization laboratory. For many patients, however, that anatomy has already been captured, often in considerable detail, by coronary CT angiography (CCTA) performed earlier in the clinical pathway. This article considers how this dataset can be used to plan the procedure, an approach referred to as CT-guided PCI.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
